Johnson & Johnson (NYSE:JNJ) has released one-year results from Phase 3 clinical trials indicating that its psoriasis treatment ICOTYDE maintained strong skin clearance outcomes through 52 weeks.
Data from the ICONIC-ADVANCE 1 and 2 trials showed that complete skin clearance rates improved over time. In the studies, clearance increased from 41% to 49% and from 33% to 48% between weeks 24 and 52 among patients receiving ICOTYDE. Participants who switched from placebo to the treatment at week 16 achieved comparable clearance rates by week 52.
The results were presented at the American Academy of Dermatology Annual Meeting. ICOTYDE is currently approved in the United States for the treatment of moderate-to-severe plaque psoriasis in adults and in pediatric patients aged 12 and older who weigh at least 40 kilograms.
In a separate adolescent trial known as ICONIC-LEAD, close to 60% of patients achieved fully clear skin after 52 weeks, while 86% reached a PASI 90 response at the one-year mark. Researchers reported that the treatment’s safety profile remained consistent with earlier stages of the trials, with no new safety concerns identified.
ICOTYDE is an oral peptide therapy that works by blocking the IL-23 receptor and is administered once daily. The drug was co-discovered with Protagonist Therapeutics, while Johnson & Johnson holds exclusive global rights for its development and commercialization.
The company is also evaluating ICOTYDE in clinical studies for additional conditions including psoriatic arthritis, ulcerative colitis and Crohn’s disease.